These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25051981)

  • 21. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
    Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors.
    Panousis D; Xepapadakis G; Lagoudianakis E; Karavitis G; Salemis N; Koronakis N; Patsouris E; Koronarchis D; Grosomanidis D; Chryssikos G; Ntasiou P; Kyriakidou V; Athanassiadou AM; Athanassiadou P
    J BUON; 2013; 18(4):879-85. PubMed ID: 24344012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermal lymphatic invasion and inflammatory breast cancer are independent predictors of outcome after postmastectomy radiation.
    Abramowitz MC; Li T; Morrow M; Sigurdson ER; Anderson P; Nicolaou N; Freedman G
    Am J Clin Oncol; 2009 Feb; 32(1):30-3. PubMed ID: 19194121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggressive Subsets of Metastatic Triple Negative Breast Cancer.
    Singh J; Asad S; Zhang Y; Nock W; Adams E; Damicis A; Ramaswamy B; Williams N; Parsons HA; Adalsteinsson VA; Winer EP; Lin NU; Partridge AH; Overmoyer B; Stover DG
    Clin Breast Cancer; 2020 Feb; 20(1):e20-e26. PubMed ID: 31631016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
    Zhang J; Wang Y; Yin Q; Zhang W; Zhang T; Niu Y
    Int J Clin Exp Pathol; 2013; 6(7):1380-91. PubMed ID: 23826420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery.
    Rosso KJ; Tadros AB; Weiss A; Warneke CL; DeSnyder S; Kuerer H; Ueno NT; Stecklein SR; Woodward WA; Lucci A
    Ann Surg Oncol; 2017 Oct; 24(10):2981-2988. PubMed ID: 28766220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.
    Warren LE; Guo H; Regan MM; Nakhlis F; Yeh ED; Jacene HA; Hirshfield-Bartek J; Overmoyer BA; Bellon JR
    Ann Surg Oncol; 2015 Aug; 22(8):2483-91. PubMed ID: 25791789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.
    Knudsen ES; Dervishaj O; Kleer CG; Pajak T; Schwartz GF; Witkiewicz AK
    Cell Cycle; 2013 Jul; 12(13):2042-50. PubMed ID: 23759596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.
    Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH
    Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily radiation therapy for inflammatory breast cancer.
    Brown L; Harmsen W; Blanchard M; Goetz M; Jakub J; Mutter R; Petersen I; Rooney J; Stauder M; Yan E; Laack N
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):997-1003. PubMed ID: 24721591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
    Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
    Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
    Hirko KA; Regan MM; Remolano MC; Schlossman J; Harrison B; Yeh E; Jacene H; Nakhlis F; Block C; Rosenbluth JM; Garrido-Castro AC; Overmoyer BA
    Am J Clin Oncol; 2021 Sep; 44(9):449-455. PubMed ID: 34149037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying factors that impact survival among women with inflammatory breast cancer.
    Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
    Ann Oncol; 2012 Apr; 23(4):870-5. PubMed ID: 21765048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory Breast Cancer at the Extremes of Age.
    Adesoye T; Babayemi O; Postlewait LM; DeSnyder SM; Sun SX; Woodward WA; Ueno NT; Hunt KK; Lucci A; Teshome M
    Ann Surg Oncol; 2021 Oct; 28(10):5626-5634. PubMed ID: 34292426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival.
    Kindts I; Buelens P; Laenen A; Van Limbergen E; Janssen H; Wildiers H; Weltens C
    Breast; 2017 Apr; 32():18-25. PubMed ID: 28012411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.